Table 2.
Hematologic, cytogenetic, and molecular response rates during the core phase of study
| Response | Week 6 | Week 12 | Week 24 | Week 36 | Week 48 |
|---|---|---|---|---|---|
| CHR, n (%) | 40 (90.9) | 37 (84.1) | 38 (86.4)* | 29 (65.9) | 25 (56.8) |
| CCyR, n (%) | 21 (47.7) | 19 (43.2) | 24 (54.5)* | 16 (36.4) | 15 (34.1) |
| CMR, n (%) | 21 (47.7) | 21 (47.7) | 18 (40.9) | 18 (40.9) | 16 (36.4) |
| MMR, n (%) | 15 (34.1) | 11 (25.0) | 14 (31.8)* | 8 (18.2) | 6 (13.6) |
Response rate was reported as the number of patients with response/number of total patients in the study. To be conservative, participants with missing postbaseline values were imputed as nonresponders.
*
Response at week 24 includes 1 participant who was assessed at week 20.